Categories: Finances

Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration

EYLEA HD shows sustained vision and anatomical improvements over three years, allowing extended dosing intervals in wAMD patients.

Source link

nasdaqpicks.com

Recent Posts

SoftBank swings to $2.4 billion loss in Q3 as value of Vision Fund’s holdings take a hit

SoftBank Group Corp. swung to losses for the December quarter due to a drop in…

15 seconds ago

SoftBank falls to $2.4bn loss amid plans for huge AI investments

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

7 minutes ago

Birlasoft share price hits 52-week low after Q3 result; should you buy this mid-cap IT stock or avoid?

Birlasoft share price fell over 6 per cent to hit a 52-week low of ₹472.40…

11 minutes ago

PM Narendra Modi to visit US: What’s on agenda?

Prime Minister Narendra Modi has embarked on a significant two-nation visit, starting with France from…

14 minutes ago

Equity inflows dip 4% on market volatility

The inflows into mutual fund equity schemes dipped four per cent last month to ₹39,688…

20 minutes ago

Ashok Leyland Q3 Results: Net profit improves 32% YoY to ₹762 crore

Ashok Leyland, the Indian flagship of the Hinduja Group announced its December quarter performance today,…

21 minutes ago